BRENTUXIMAB VEDOTIN for Diffuse large b-cell lymphoma refractory: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 7 adverse event reports in the FDA FAERS database where BRENTUXIMAB VEDOTIN was used for Diffuse large b-cell lymphoma refractory.
Most Reported Side Effects for BRENTUXIMAB VEDOTIN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 1,370 | 14.1% | 318 | 492 |
| Neuropathy peripheral | 695 | 7.2% | 82 | 174 |
| Pyrexia | 693 | 7.1% | 140 | 476 |
| Febrile neutropenia | 684 | 7.0% | 80 | 477 |
| Death | 602 | 6.2% | 601 | 125 |
| Neutropenia | 561 | 5.8% | 99 | 267 |
| Hodgkin's disease | 512 | 5.3% | 157 | 111 |
| Nausea | 392 | 4.0% | 74 | 235 |
| Diarrhoea | 385 | 4.0% | 85 | 231 |
| Anaemia | 374 | 3.9% | 89 | 223 |
| Thrombocytopenia | 358 | 3.7% | 76 | 185 |
| Weight decreased | 352 | 3.6% | 91 | 190 |
| Disease progression | 313 | 3.2% | 98 | 44 |
| Drug ineffective | 308 | 3.2% | 68 | 63 |
| Pneumonia | 302 | 3.1% | 112 | 201 |
Other Indications for BRENTUXIMAB VEDOTIN
Hodgkin's disease (4,665)
Product used for unknown indication (1,003)
Anaplastic large cell lymphoma t- and null-cell types (406)
Peripheral t-cell lymphoma unspecified (366)
Anaplastic large-cell lymphoma (358)
Cutaneous t-cell lymphoma (314)
Hodgkin's disease refractory (279)
Diffuse large b-cell lymphoma (248)
T-cell lymphoma (199)
Lymphoma (168)
Other Drugs Used for Diffuse large b-cell lymphoma refractory
RITUXIMAB (667)
EPCORITAMAB-BYSP (353)
AXICABTAGENE CILOLEUCEL (336)
BENDAMUSTINE (283)
CYCLOPHOSPHAMIDE (226)
POLATUZUMAB VEDOTIN (223)
ETOPOSIDE (165)
POLATUZUMAB VEDOTIN-PIIQ (158)
GEMCITABINE (147)
LENALIDOMIDE (143)